(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
6 Shades Brands For Seniors - 2Child influencers helped power a booming industry. It's time for a reckoning.
- 3Burkina Faso must 'forget' about democracy, military leader says
- 4FDA official discusses potential link between COVID-19 vaccines and pediatric deaths
- 5The Magnificence of Do-It-Yourself Skincare: Regular Recipes and Tips
- Italian court approves extradition to Germany of Ukrainian suspect in Nord Stream pipeline blast
- Most loved Specially prepared Espresso Mix: Which Meal Do You Adore the Most?
- Experience Is standing by: 10 Pleasant Setting up camp Areas to
- UK clothing inflation climbs as Middle East turmoil threatens wider price rises
- Instructions to Pick the Right Tires for Your Slam 1500.
- This Week In Space podcast: Episode 186 — Snow on the Moon?
- Nurturing Hacks: Shrewdness from Experienced Mothers and Fathers
- Well informed: How to Take full advantage of Your Gadgets
- The Manual for Decent European Urban communities in 2024
